



Universiteit  
Leiden  
The Netherlands

## **Consumed by a forbidden emotion: anger and aggression in patients with psychiatric disorders**

Bles, N.J. de

### **Citation**

Bles, N. J. de. (2023, April 26). *Consumed by a forbidden emotion: anger and aggression in patients with psychiatric disorders*. Retrieved from <https://hdl.handle.net/1887/3594670>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3594670>


**Note:** To cite this publication please use the final published version (if applicable).



**Published as:** de Bles, N. J., van der Does, J. E. H., Kortbeek, L. M., Hofhuis, A., van Grootheest, G., Vollaard, A. M., Schoevers, R. A., van Hemert, A. M., Penninx, B. W. J. H., Rius-Ottenheim, N., & Giltay, E. J. (2021). Toxoplasma gondii seropositivity in patients with depressive and anxiety disorders. *Brain, behavior, & immunity – health*, *11*, 100197.

# 5

Toxoplasma gondii seropositivity  
in patients with depressive and  
anxiety disorders



## Abstract

**Introduction:** *Toxoplasma gondii* (*T. gondii*) is an obligate intracellular parasite that is estimated to be carried by one-third of the world population. Latent *T. gondii* infection has been linked to several neuropsychiatric mood disorders and behaviours. The aim of the present study was to examine whether *T. gondii* seropositivity is associated with affective disorders, as well as with aggression reactivity and suicidal thoughts.

**Methods:** In the Netherlands Study of Depression and Anxiety (NESDA), *T. gondii* antibodies were assessed in patients with current depressive ( $n = 133$ ), anxiety ( $n = 188$ ), comorbid depressive and anxiety ( $n = 148$ ), and remitted disorders ( $n = 889$ ), as well as in healthy controls ( $n = 373$ ) based on DSM-IV criteria. Seropositivity was analysed in relation to disorder status, aggression reactivity and suicidal thoughts using multivariate analyses of covariance and regression analyses.

**Results:** Participants were on average 51.2 years ( $SD = 13.2$ ), and 64.4% were female. Seropositivity was found in 673 participants (38.9%). A strong positive association between *T. gondii* seropositivity and age was observed. No significant associations were found between *T. gondii* seropositivity and disorder status, aggression reactivity and suicidal thoughts. The adjusted odds ratio (OR) for any remitted disorder versus controls was 1.13 (95% CI: 0.87-1.49), and for any current disorder versus controls was 0.94 (95% CI: 0.69-1.28).

**Conclusions:** No evidence was found for a relationship between affective disorders and *T. gondii* infection in the current sample.

## Introduction

*Toxoplasma gondii* (*T. gondii*) is an obligate intracellular parasite estimated to be carried by one-third of the world's population, making it one of the most successful human parasites <sup>(1,2)</sup>. It can infect mammals and many other warm-blooded animals, with cats and other felidae as its definitive hosts for sexual reproduction and the only mammals known to shed *T. gondii* oocysts with their faeces <sup>(3)</sup>. In the intermediate host, the parasite can lead to a lifelong, latent infection in various tissues, including muscles, the eye, and the central nervous system, where it forms persistent cysts. Humans are infected by swallowing *T. gondii* tissue cysts in contaminated food (undercooked infected meat) or oocysts in water, or through environmental exposure (e.g., through gardening).

While an acute infection is commonly asymptomatic or presenting with nonspecific symptoms like fatigue or lymphadenopathy, it can in some cases lead to toxoplasmic encephalitis. In case of a congenital toxoplasmosis, most lesions will be seen in the eyes and in the brain (e.g., intracranial calcifications, hydrocephalus). The parasite will not be cleared, and, after an acute symptomatic phase, the parasite will be present as a latent infection that is commonly thought to be asymptomatic <sup>(4)</sup>. However, there are indications of more subtle behavioural or psychological consequences. Evidence is also accumulating for an association between *T. gondii* infection and schizophrenia <sup>(5)</sup>. Additionally, an increase in *T. gondii* immunoglobulin G (IgG) titers, but not in immunoglobulin M (IgM), was found among patients with schizophrenia <sup>(6,7)</sup>. This may implicate a latent *T. gondii* infection rather than an acute infection where both IgG and IgM titers would have increased. Increased IgG titers are thought to represent reactivation with release of tachyzoites, which may lead to psychopathology <sup>(8)</sup>. The interest in the possible link between *T. gondii* and depression was sparked by a case report <sup>(9)</sup>, describing a depressed patient who possibly remitted after antibiotic treatment of his latent *T. gondii* infection. Subsequent studies investigated the possible link between *T. gondii* infection and depression, yet provided no clear consensus on this association. Several studies found positive associations between depressive symptoms and *T. gondii* seropositivity <sup>(10-12)</sup>. Additionally, two studies found a dose-response relationship, with higher IgG titers associated with higher depressive symptoms <sup>(13, 14)</sup>. However, a negative association between diagnoses of depression and *T. gondii* seropositivity in women was observed in a cross-sectional study of 1486 subjects <sup>(15)</sup>. Taking both genders together in one analysis, however, the association with *T. gondii* seropositivity did not longer persist. In concordance, a systematic review including

ten studies with data on major depressive disorder (MDD), found no support for a significant association between *T. gondii* infection and depression, with an odds ratio (OR) of only 1.21 (95% confidence interval [CI]: 0.86-1.70)<sup>(16)</sup>, which is in line with recent cross-sectional studies on MDD and *T. gondii* infection<sup>(17-19)</sup>.

Besides depression, anxiety disorders have also been studied in relation to *T. gondii* infection. An association between *T. gondii* seropositivity and generalized anxiety disorder (GAD) has been reported, with ORs ranging from 2.05 to 2.25<sup>(11, 14, 18)</sup>, with an even higher OR of 4.17 among children<sup>(20)</sup>. On the other hand, a large population-based cross-sectional study of 1846 participants<sup>(17)</sup> reported no significant associations between *T. gondii* infection and GAD or panic disorder (PD).

Furthermore, latent *T. gondii* infection has been linked to behavioural changes such as increased feelings of aggression and anger<sup>(12, 21, 22)</sup> and self-directed violence (e.g., suicide attempts, completed suicide, and self-directed violence)<sup>(10, 23-27)</sup>. A study of 1000 participants without any psychiatric diagnoses showed an association between *T. gondii* seropositivity and trait reactive aggression among women<sup>(22)</sup>, which was in line with a smaller study among 70 female veterans showing a relationship between *T. gondii* seropositivity and higher anger scores<sup>(12)</sup>. Another previous study on *T. gondii* seropositivity and anger included both healthy participants and psychiatric patients. This cross-sectional study of 358 adults found an association between *T. gondii* seropositivity and higher aggression and impulsivity. Additionally, seropositivity was highest in subjects with intermittent explosive disorder (21.8% of  $n = 110$ ), compared to healthy controls (9.1% of  $n = 110$ ), and other psychiatric patients (16.7% of  $n = 138$ )<sup>(21)</sup>. Several studies on self-harm have also been conducted. Cross-sectional and case-control studies focusing on suicide attempts and *T. gondii* infection found evidence for a relationship with seropositivity, with ORs ranging from 1.57 to 7.12<sup>(10, 25, 28)</sup>, and antibody titers, meaning that higher IgG titers were associated with suicide attempts<sup>(23-25, 28)</sup>. In a large register-based prospective cohort study among 45,788 women after childbirth, *T. gondii*-infected mothers had a relative risk of self-directed violence of 1.53 (95% CI, 1.27-1.85) versus non-infected counterparts<sup>(26)</sup>. Thus, there seems to be an association between *T. gondii* latent infection on the one hand and (self-directed) aggression and suicidality on the other hand.

We aimed to further examine the link between *T. gondii* infection and (comorbid) depressive and anxiety disorders in a large cohort study. Based on existing literature, we hypothesized [1] that *T. gondii* seropositivity is associated with the presence and severity of depressive and anxiety disorders, and [2] that *T. gondii* seropositivity is associated with aggression reactivity and suicidal thoughts.

## Methods

### Participants

Participants were selected from the Netherlands Study of Depression and Anxiety (NESDA), an ongoing multisite, naturalistic, longitudinal cohort study. NESDA was designed to examine the long-term course and consequences of depressive and anxiety disorders. A total of 2981 participants (18–65 years) were enrolled at baseline. This population was composed of participants with current or remitted depressive and anxiety disorders, and comorbid depressive and anxiety disorders. The control group consisted of participants without lifetime psychiatric disorders. Participants were recruited from the community, primary care, and specialized (mental) health care in the vicinity of the clinical sites (i.e., Amsterdam [Northwest], Leiden [Southwest], Groningen [Northeast]). Exclusion criteria were (1) the presence of other psychiatric disorders (e.g., psychotic, obsessive–compulsive, bipolar, or severe addiction disorder): and (2) not being fluent in Dutch. All participants gave written informed consent before enrolment, and the ethical committees of participating universities (VU University Medical Centre, Leiden University Medical Centre, and University Medical Centre Groningen) granted ethical approval. A more detailed description of NESDA is given elsewhere <sup>(29)</sup>.

For the current cross-sectional study, data was gathered at the 6th wave at 9-year follow-up between 2014 and 2017. Participants who completed the 6th wave totalled 2069 (69.4%), of whom 1731 titers were obtained and used for the current analyses. Excluded participants were younger ( $p = 0.004$ ), more often women ( $p < 0.001$ ) and had more fear symptoms ( $p < 0.001$ ) compared to the sample included in the current study.

### Measurements

#### *Toxoplasma gondii* IgG antibodies

Citrated plasma samples were kept frozen at  $-80\text{ }^{\circ}\text{C}$  until assayed for *T. gondii* IgG antibodies. In response to the parasite, *T. gondii* IgG antibodies are produced within the first two to three weeks after infection, peaks at 3 months and, although it can decrease slowly, remains detectable over the individual's lifetime. IgG antibody levels were assayed in duplicate in plasma using a sandwich Enzyme Linked Immunosorbent Assay (ELISA) with a plasma dilution of 1:20 (adapted from a previously described method <sup>(30)</sup>). Detection of IgG antibodies in citrated plasma was first validated in a subpopulation of 100 participants, by comparing *T. gondii* seropositivity in citrated

## Chapter 5

plasma from the 6th wave with serum samples from the 5th wave. The agreement for IgG antibodies in serum and citrated plasma was 100% (Suppl. Fig. 1). The time span between blood collection at these waves ranged from 28 to 56 months. The sensitivity and specificity of the ELISA were 99–100% and 90–99% respectively. The antigen is derived from a crude extract of a *Toxoplasma* RH strain, the conjugate is a peroxidase-labelled anti-human IgG conjugate (Dako, Denmark). A cut-off serum was used, and its optical density (OD) value was allowed to vary between 0.10 and 0.30. The extinction value of the tested sample and the cut-off serum was used to calculate a ratio. A subject with a ratio of at least 1.0 was considered to be seropositive for *T. gondii*<sup>(31)</sup>.

### *Depressive and anxiety disorders*

Diagnoses of depression (i.e., MDD, dysthymia) and anxiety disorders (i.e., social phobia [SP], PD, GAD, agoraphobia [AP]) were established with the Composite International Diagnostic Interview (CIDI; WHO version 2.1). The CIDI is a fully structured clinical interview based on criteria of the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV<sup>(32)</sup>). Based on the CIDI information, all 1731 NESDA participants were divided into the following psychopathology groups: [1] healthy participants who have no current and past history of psychiatric disorders ( $n = 373$ ); [2] participants with a lifetime history of a depressive or anxiety disorder, but not in the last 6 months ( $n = 889$ ); [3] patients with a current depressive ( $n = 133$ ) or [4] anxiety disorder ( $n = 188$ ); and [5] patients with current comorbid depressive and anxiety disorders ( $n = 148$ ). The CIDI was established at the same day of blood collection.

### *Symptom severity*

The severity of depressive symptoms was assessed with the Inventory of Depressive Symptomatology (self-report version; IDS-SR)<sup>(33, 34)</sup>. The IDS-SR is a 30-item questionnaire scored on a 4-point Likert scale (0–3), with sum scores ranging from 0 to 84 (28 out of 30 items are rated). The internal consistency (i.e., Cronbach's alpha) of the IDS-SR in our sample was 0.89. The Beck Anxiety Inventory (BAI) is a 21-item self-report questionnaire for measuring the somatic symptoms of anxiety<sup>(35)</sup>. It uses a 4-point Likert scale (0–3), with total scores ranging from 0 to 63. The current sample showed an internal consistency (i.e., Cronbach's alpha) of 0.92. Additionally, the 15-item self-rating Fear Questionnaire (FQ) was obtained to measure phobias and, particularly, related avoidance<sup>(36)</sup>, on a 9-point Likert scale (0–8), with total scores ranging from 0 to 120 and a Cronbach's alpha of 0.89 in the current sample. The abbreviated 11-item version



of the Penn State Worry Questionnaire (PSWQ) was assessed to measure pathological worry and general anxiety<sup>(37)</sup>. Items are scored on a 5-point Likert scale (1–5), with sum score ranging from 11 to 55. Our sample presented an internal consistency (i.e., Cronbach's alpha) of 0.96.

#### *Cognitive reactivity*

The revised Leiden Index of Depression Sensitivity (LEIDS-R) is a 34-item self-report questionnaire developed to measure cognitive reactivity to sad mood<sup>(38,39)</sup>. Items are divided into six reactivity subscales, of which the subscales aggression and hopelessness/suicidality were used in the current wave. Items are filled out on a 5-point Likert scale ranging from 0 to 4. The aggression subscale constitutes of 6 items (e.g., 'In a sad mood, I am bothered more by aggressive thoughts'), with a maximum score of 24. The hopelessness/suicidality subscale constitutes of 5 items (e.g., 'When I feel sad, more thoughts of dying or harming myself go through my mind'), with a maximum score of 20. The internal consistency (i.e., Cronbach's alpha) of the LEIDS-R subscales in our sample were 0.83 and 0.87, respectively.

#### *Covariates*

Sociodemographic covariates consisted of sex, age, education (in years), North European ancestry (yes/no), and clinical site location (i.e., Amsterdam, Leiden, Groningen). Age was divided into four age groups (i.e., 40 and younger; 41–50; 51–60; 61 and older). Body Mass Index (BMI) was calculated based on measured weight and height.

#### **Statistical analyses**

Sociodemographic characteristics were described within the *T. gondii* seronegative and seropositive groups using chi-squared tests for categorical variables and t-tests (ANOVA) for continuous variables. We also performed multivariable logistic regression analyses to examine the associations of *T. gondii* seropositivity according to demographic characteristics.

Chi-squared tests for independent samples were conducted to compare the prevalence of seropositivity among psychiatric disorders. Using multivariable logistic regression, these comparisons were repeated, adjusting for sex, age, level of education, North European ancestry, BMI, and clinical site location. Subsequently, we adjusted the full model according to previous mentioned sociodemographic variables and healthy controls, remitted depression and/or anxiety, and current dysthymia,

MDD, SP, PD, AP, and GAD. A forest plot was used to examine the OR (with 95% CI) of seropositivity among psychiatric diagnoses. In addition to testing for dichotomous seropositivity, sensitivity analyses were performed using multivariable linear regression for the continuous level of *T. gondii* IgG antibodies expressed as the ratio of OD values. The level of *T. gondii* IgG antibodies was naturally log transformed in order for its distribution to approach normality.

We also performed t-tests for independent samples to examine the association of symptom severity measures and cognitive reactivity (i.e., aggression and suicidality) with seropositivity. Using analysis of covariance (ANCOVA), analyses were repeated adjusting for sex, age, level of education, North European ancestry, BMI, and clinical site location. A second forest plot was used to examine the association of seropositivity with symptom severity and cognitive reactivity. Subsequently, sensitivity analyses were performed for the transformed level of *T. gondii* IgG antibodies in multivariable linear regression. A two-tailed significance level of  $p < 0.05$  was considered statistically significant for all analyses. The Benjamini-Hochberg (B-H) correction was performed in order to correct for a false discovery rate (FDR) in multiple comparisons<sup>(40)</sup>. Analyses were performed using IBM SPSS statistical software (version 25, IBM Corp.).


## Results

The mean age of the participants ( $N = 1731$ ) was 51.2 years ( $SD = 13.2$ ), and 64.4% were female. As shown in Fig. 1, 673 participants (38.9%) were seropositive for *T. gondii* antibodies. The odds of being seropositive for *T. gondii* increased strongly with age. *T. gondii* seroprevalence differed per clinical site location, ranging from 30.0% in Groningen (Northeast), 41.9% in Amsterdam (Northwest), to 44.6% in Leiden (Southwest). The area remained independently associated with *T. gondii* infection after adjustment for demographic characteristics. However, this was only true for Groningen compared to Amsterdam and Leiden, but not for Amsterdam and Leiden compared to each other.


Fig. 2 shows the adjusted odds of being seropositive for depressive and anxiety disorders. Healthy controls were taken as the reference group in Model 1. No associations were found between seropositivity and depressive and anxiety diagnoses after adjusting for sociodemographic variables. The odds ratio (OR) for any remitted disorder versus controls was 1.13 (95% CI: 0.87-1.49), and for any current disorder versus controls was 0.94 (95% CI: 0.69-1.28). The fully adjusted model only showed a significant negative association between *T. gondii* seropositivity and SP ( $OR = 0.62$ ;

95% CI: 0.39-0.96). However, after B-H correction, the result was no longer deemed statistically significant. When these analyses were repeated for *T. gondii* IgG antibodies, no significant associations were found in the models adjusting for sociodemographic variables. The fully adjusted model resulted in a significant negative association with *T. gondii* and MDD ( $\beta = -0.09$ ;  $p = 0.008$ ), and with *T. gondii* and SP ( $\beta = -0.06$ ;  $p = 0.03$ ; Suppl. Table 2). Again, these associations were no longer deemed statistically significant after B-H correction.


As shown in Fig. 3, no mean differences were found between seropositive and seronegative subjects on symptom severity measures (i.e., IDS-SR, BAI, FQ, and PSWQ), aggression reactivity and suicidal thoughts. These associations remained non-significant after adjustment for sociodemographic variables. All severity measures were also tested for seropositivity in diagnostic strata (i.e., controls, remitted, and current psychopathology), in which no important differences in effect sizes among the groups were found, and none of the comparisons were statistically significant (data not shown). Analyses for a crude and adjusted model were repeated for antibody levels and also found no significant relationships (Suppl. Table 2).



**Fig 1.** Characteristics of the study sample (N = 1731) according *T. gondii* seropositivity and the adjusted odds ratios for all independent variables in one multivariable logistic regression model.  
 Note: BMI = Body Mass Index; Chi-square values have been computed for categorical variables, ANOVA for interval variables; Education in years and BMI were studied per 5 units (i.e., 5 kg/m<sup>2</sup>) increase.



**Fig. 2.** The (adjusted) odds ratios of seropositivity for depressive and anxiety disorders. Model 1 adjusted for sex, age, level of education, North European ancestry, BMI, and clinical site location with healthy controls taken as the reference group. Model 2 adjusted for the beforementioned sociodemographic variables, healthy controls, remitted depression and/or anxiety, and current dysthymia, MDD, SP, PD, AP, and GAD.



**Fig. 3.** Mean differences (with standard errors in parentheses) between IgG seronegative and seropositive subjects on symptom severity measures (i.e., IDS-SR, BAI, FQ, and PSWQ), aggression reactivity and suicidal thoughts. Adjusted for sex, age, level of education, North European ancestry, BMI, and clinical site location. Note: IDS-SR = Inventory of Depressive Symptomatology – self-report; BAI = Beck Anxiety Inventory; FQ = Fear Questionnaire; PSWQ = Penn State Worry Questionnaire; LEIDS-R = Leiden Index of Depression Sensitivity – Revised.

## Discussion

This study aimed to examine the link between *T. gondii* specific IgG antibodies and disorder status, aggression reactivity and suicidal thoughts. No significant association was found for *T. gondii* seropositivity in relation to disorder status. Similarly, no significant associations were found for *T. gondii* seropositivity in relation to aggression reactivity or suicidal thoughts. *T. gondii* seropositivity was strongly associated with older age.

Our findings of a lack of the association between *T. gondii* seropositivity and depression diagnosis is in line with the before-mentioned meta-analysis<sup>(16)</sup> and several population-based cross-sectional studies<sup>(17-19)</sup>. We extended their findings by showing that there was no association neither with self-reported depressive symptoms nor with observer-rated depression diagnoses through standardized diagnostic psychiatric interviews. Although, some significant associations between seroprevalence and depressive symptoms were found in some studies, these findings were done in studies with smaller sample sizes of at most 51 seropositive subjects, increasing the risk of chance findings<sup>(10-12)</sup>. A dose-response relationship, with higher antibody titers being associated with an increase in depressive symptoms, was reported in two studies<sup>(13, 14)</sup>. The majority of studies, however, did not find any associations<sup>(11, 17, 18)</sup>, which was in line with our findings. Previous inconsistencies could be explained neither by differences in age distribution nor by the strain hypothesis which states that strains of *T. gondii* differ in virulence and in ability to influence human behaviour<sup>(41-43)</sup>. Hence, the current study bolsters the rejection of the hypothesis that *T. gondii* seropositivity is associated with the presence and severity of major depression.

In line with our findings on depressive status, we did not find associations between *T. gondii* seropositivity and anxiety disorders. This was concordant with population-based studies of 1846 and 7712 participants respectively that did not find an association between *T. gondii* and GAD or PD<sup>(17)</sup>, and between *T. gondii* and PD, AP, or SP<sup>(14)</sup>, as established with the CIDI. The latter study only found a significant relationship between *T. gondii* seropositivity and GAD, yet no corrections for multiple comparisons were used<sup>(14)</sup>. Two other large population-based studies reported a significant relationship between *T. gondii* seropositivity and GAD as established with a telephone survey<sup>(18)</sup>, and general anxiety based on a screening tool<sup>(11)</sup>. These results contradict animal studies that suggest reduced anxiety-like behaviour in *T. gondii* infected rodents<sup>(44, 45)</sup>.

The association of seropositivity with aggression reactivity was inconsistent with previously reported studies on self-reported anger and aggressive behaviour<sup>(12, 21, 22)</sup>. However, those studies used other but related constructs (i.e., anger mood, aggressive tendencies as a personality trait, and a history of actual aggressive behaviour), although one study also measured aggression reactivity<sup>(22)</sup>. The latter study found significant results only among women. Importantly, aggressive reactivity measures thoughts rather than actual behaviour like the history of aggression. The current study also took into account self-directed aggression by measuring suicidal thoughts. No differences were found between seropositive and seronegative subjects, which contradicts the previous studies that found an association between *T. gondii* infection and suicidality<sup>(10, 23-26, 28)</sup>. However, some of these studies reported inconsistent findings, with a significant relationship of suicide attempts with seropositivity but not with antibody levels<sup>(10)</sup>, or the inverse<sup>(23, 24)</sup>. Furthermore, the significant associations that were reported in Okusaga et al. (2011) were only found among patients under 38, while no association for seropositivity or antibody levels was found among older patients. In addition, as most of these studies had a cross-sectional design, there remains the possibility of reverse causation, meaning that disorder status or behavioural traits may have affected the risk of *T. gondii* infection<sup>(18, 22, 27)</sup>.

The seroprevalence of *T. gondii* strongly increased with age, which is a result of cumulative seropositivity and is in line with previous studies<sup>(2, 31, 46)</sup>. Although some studies found differences between males and females<sup>(15, 22)</sup>, others, including ours, did not<sup>(18)</sup>. Our finding that seroprevalence was independently associated with geographical regions was concordant with previous results from the Netherlands<sup>(31)</sup>. These previous results indicated highest seroprevalence rates in the Northwest (43%) and Southwest (37%) regions, compared to other provinces in the Netherlands. They also found a steepest rise in seroprevalence in the age group 15–49 years. Importantly, the current sample had a mean age of 51.2 years. Furthermore, a substantial part of the sample was recruited in Western regions. These two factors may explain our relatively high seroprevalence rate of 38.9%.

This study has several strengths. We investigated seroprevalence in a large cohort that included patients without lifetime psychiatric disorders (“control subjects”), with (current and remitted) depressive and anxiety disorders, or comorbid depressive and anxiety disorders. Diagnoses were established with the CIDI (WHO version 2.1), a comprehensive observer-rated instrument with high interrater reliability<sup>(47)</sup>, high test–retest reliability<sup>(48)</sup> and high validity for depressive and anxiety disorders<sup>(49, 50)</sup>. Moreover, we not only stratified participants according to their diagnosis, but also

## Chapter 5

studied symptom severity levels. Furthermore, blood samples were assayed according to a reliable standardized in-house ELISA protocol of the RIVM, with a sensitivity and specificity of 99–100% and 90–99% respectively. The methods, antigens and controls have not altered over the past 35 years, making the results of the different studies comparable.

Limitations of the current study must also be mentioned. The cross-sectional design of the current study hampers inferences of causation, therefore prospective studies are still needed. A second limitation is that the difference between strains (i.e., Types I, II, III, and atypical or recombinant strains) which causes chronic infection is not accounted for. Since we assume that infections with distinct strains all result in increased titers, seropositivity itself cannot be used to differentiate between strains or help to unravel differences in (neuro)virulence between strains. We also did not exclude other infections and immune system diseases. Some studies suggest that *T. gondii* antibodies may only be an indicator of previous contacts with cats, with these cats carrying other pathogens such as *Bartonella henselae* affecting mental health<sup>(51-53)</sup>. A last limitation is that we did not study actual suicidal and aggressive behaviours.

In conclusion, the current study does not support the hypothesis that *T. gondii* seropositivity is associated with depressive or anxiety disorders, or with aggressive and suicidal thoughts. In light of previous studies and our new findings, it seems unlikely that *T. gondii* seropositivity plays a major role in the risk of affective disorders, suicidality and aggressive thoughts.

### Data availability statement

An a priori analysis plan for this study was approved by the principal investigator of NESDA and the NESDA board. Because of ethical and legal restrictions, data involving clinical participants are not included in the manuscript or made available in a public repository. However, subject to approval, data are available upon request from the NESDA Data Access Committee ([nesda@ggzingeest.nl](mailto:nesda@ggzingeest.nl)).

### Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.



## Acknowledgements

We would like to thank Manal el Ameri and Denise Hoek-van Deursen for their highly appreciated work in the lab. The infrastructure for the NESDA study ([www.nesda.nl](http://www.nesda.nl)) is funded through the Geestkracht program of the Netherlands Organisation for Health Research and Development (ZonMw, grant number 10-000-1002) and financial contributions by participating universities and mental health care organizations (VU University Medical Center, GGZ inGeest, Leiden University Medical Center, Leiden University, GGZ Rivierduinen, University Medical Center Groningen, University of Groningen, Lentis, GGZ Friesland, GGZ Drenthe, Rob Giel Onderzoekscentrum).

## Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.bbih.2020.100197>.

## References


1. Halonen SK, Weiss LM. Toxoplasmosis. *Handb Clin Neurol*. 2013;114:125-45.
2. Montoya JG, Liesenfeld O. Toxoplasmosis. *The Lancet*. 2004;363(9425):1965-76.
3. Miller CM, Boulter NR, Ikin RJ, Smith NC. The immunobiology of the innate response to *Toxoplasma gondii*. *International journal for parasitology*. 2009;39(1):23-39.
4. Saadatnia G, Golkar M. A review on human toxoplasmosis. *Scandinavian Journal of Infectious Diseases*. 2012;44(11):805-14.
5. Fuglewicz AJ, Piotrowski P, Stodolak A. Relationship between toxoplasmosis and schizophrenia: A review. *Adv Clin Exp Med*. 2017;26(6):1031-6.
6. Ibrahim Ali M, Abdel Gawad Mousa Ismail M, Abd-Elftah Abd-Allah G, Abdel-Latif M, Mohamed Shaapan R, Salah H, et al. Toxoplasmosis in Schizophrenic Patients: Immune-diagnosis and Serum Dopamine Level. *Pak J Biol Sci*. 2020;23(9):1131-7.
7. Leweke FM, Gerth CW, Koethe D, Klosterkötter J, Ruslanova I, Krivogorsky B, et al. Antibodies to infectious agents in individuals with recent onset schizophrenia. *European archives of psychiatry and clinical neuroscience*. 2004;254(1):4-8.
8. Hester J, Mullins J, Sa Q, Payne L, Mercier C, Cesbron-Delauw M-F, et al. Toxoplasma gondii antigens recognized by IgG antibodies differ between mice with and without active proliferation of tachyzoites in the brain during the chronic stage of infection. *Infection and immunity*. 2012;80(10):3611-20.
9. Kar N, Misra B. Toxoplasma seropositivity and depression: a case report. *BMC Psychiatry*. 2004;4:1.
10. Bak J, Shim SH, Kwon YJ, Lee HY, Kim JS, Yoon H, et al. The Association between Suicide Attempts and *Toxoplasma gondii* Infection. *Clin Psychopharmacol Neurosci*. 2018;16(1):95-102.
11. Bay-Richter C, Buttenschon HN, Mors O, Eskelund A, Budac D, Kaerlev L, et al. Latent toxoplasmosis and psychiatric symptoms - A role of tryptophan metabolism? *Journal of psychiatric research*. 2019;110:45-50.
12. Duffy AB, TM; Brenner, LA; Beckstead, JW; Seyfang, A; Postolache, TT; Groer, MW. Relationship between *Toxoplasma gondii* and mood disturbance in women veterans. *Mil Med*. 2015;180(6):621-5.
13. Groer MW, Yolken RH, Xiao JC, Beckstead JW, Fuchs D, Mohapatra SS, et al. Prenatal depression and anxiety in *Toxoplasma gondii*-positive women. *Am J Obstet Gynecol*. 2011;204(5):433 e1-7.
14. Suvisaari J, Torniainen-Holm M, Lindgren M, Harkanen T, Yolken RH. *Toxoplasma gondii* infection and common mental disorders in the Finnish general population. *Journal of affective disorders*. 2017;223:20-5.
15. Flegr J, Escudero DQ. Impaired health status and increased incidence of diseases in *Toxoplasma*-seropositive subjects – an explorative cross-sectional study. *Parasitology*. 2016;143(14):1974-89.
16. Sutherland AL, Fond G, Kuin A, Koeter MW, Lutter R, van Gool T, et al. Beyond the association. *Toxoplasma gondii* in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis. *Acta psychiatrica Scandinavica*. 2015;132(3):161-79.

17. Gale SB, BL; Berrett, A; Erickson, LD; Hedges, DW. Association between latent toxoplasmosis and major depression, generalised anxiety disorder and panic disorder in human adults. *Folia Parasitologica*. 2014;61(4):285-92.
18. Markovitz AA, Simanek AM, Yolken RH, Galea S, Koenen KC, Chen S, et al. Toxoplasma gondii and anxiety disorders in a community-based sample. *Brain, Behavior, and Immunity*. 2015;43:192-7.
19. Sugden KM, TE; Pinto, L; Poulton, R; Williams, RS; Caspi, A. Is Toxoplasma Gondii Infection Related to Brain and Behavior Impairments in Humans? *PloS one*. 2016;11(2):e0148435.
20. Akaltun I, Kara SS, Kara T. The relationship between Toxoplasma gondii IgG antibodies and generalized anxiety disorder and obsessive-compulsive disorder in children and adolescents: a new approach. *Nord J Psychiatry*. 2018;72(1):57-62.
21. Coccaro EL, R; Groer, MW; Can, A; Cousins-Read, M; Postolache, TT. Toxoplasma gondii infection: relationship with aggression in psychiatric subjects. *The Journal of clinical psychiatry*. 2016;77(3):334-41.
22. Cook TB, LA; Cloninger, CR; Langenberg, P; et al. "Latent" infection with Toxoplasma gondii: Association with trait aggression and impulsivity in healthy adults. *Journal of psychiatric research*. 2015;60:87-94.
23. Alvarado-Esquivel C, Sánchez-Anguiano LF, Arnaud-Gil CA, López-Longoria JC, Molina-Espinoza LF, Estrada-Martínez S, et al. Toxoplasma gondii infection and suicide attempts: a case-control study in psychiatric outpatients. *The Journal of nervous and mental disease*. 2013;201(11):948-52.
24. Arling TA, Yolken RH, Lapidus M, Langenberg P, Dickerson FB, Zimmerman SA, et al. Toxoplasma gondii antibody titers and history of suicide attempts in patients with recurrent mood disorders. *The Journal of nervous and mental disease*. 2009;197(12):905-8.
25. Okusaga O, Langenberg P, Sleemi A, Vaswani D, Giegling I, Hartmann AM, et al. Toxoplasma gondii antibody titers and history of suicide attempts in patients with schizophrenia. *Schizophrenia research*. 2011;133(1-3):150-5.
26. Pedersen MG, Mortensen PB, Norgaard-Pedersen B, Postolache TT. Toxoplasma gondii infection and self-directed violence in mothers. *Archives of general psychiatry*. 2012;69(11):1123-30.
27. Sutherland AL, Kuin A, Kuiper B, van Gool T, Leboyer M, Fond G, et al. Driving us mad: the association of Toxoplasma gondii with suicide attempts and traffic accidents - a systematic review and meta-analysis. *Psychological medicine*. 2019;49(10):1608-23.
28. Zhang Y, Traskman-Bendz L, Janelidze S, Langenberg P, Saleh A, Constantine N, et al. Toxoplasma gondii immunoglobulin G antibodies and nonfatal suicidal self-directed violence. *The Journal of clinical psychiatry*. 2012;73(8):1069-76.
29. Penninx BWJH, Beekman ATF, Smit JH, Zitman FG, Nolen WA, Spinhoven P, et al. The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods. *International Journal of Methods in Psychiatric Research*. 2008;17(3):121-40.
30. Ruitenbergh EJ, van Knapen F. The Enzyme-Linked Immunosorbent Assay and Its Application to Parasitic Infections. *The Journal of Infectious Diseases*. 1977;136(Supplement\_2):S267-S73.

## Chapter 5

31. Hofhuis AvP, W; van Duynhoven, YT; Nijhuis, CD; Mollema, L; van der Klis, FR; Havelaar, AH; Kortbeek, LM. Decreased prevalence and age-specific risk factors for *Toxoplasma gondii* IgG antibodies in The Netherlands between 1995/1996 and 2006/2007. *Epidemiol Infect.* 2011;139(4):530-8.
32. APA. Diagnostic and Statistical manual of mental disorders 4th edition (DSM-IV). Washington, DC: British Library Cataloguing in Publication Data. 1994.
33. Rush AG, CM; Basco, MR; Jarrett, RB; Trivedi, MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. *Psychological medicine.* 1996;26(3):477-86.
34. Rush AJ, Giles DE, Schlessner MA, Fulton CL, Weissenburger J, Burns C. The Inventory for Depressive Symptomatology (IDS): preliminary findings. *Psychiatry research.* 1986;18(1):65-87.
35. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. *Journal of consulting and clinical psychology.* 1988;56(6):893-7.
36. Marks IM, Mathews AM. Brief standard self-rating for phobic patients. *Behaviour research and therapy.* 1979;17(3):263-7.
37. Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and validation of the penn state worry questionnaire. *Behaviour research and therapy.* 1990;28(6):487-95.
38. Van der Does A, Williams JLU. Leiden index of depression sensitivity-revised (LEIDS-R). 2003.
39. Van der Does W. Cognitive reactivity to sad mood: structure and validity of a new measure. *Behaviour research and therapy.* 2002;40(1):105-20.
40. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. 1995;57(1):289-300.
41. Abdoli A. *Toxoplasma gondii* and neuropsychiatric diseases: strain hypothesis. *Neurol Sci.* 2013;2013(34):1697-8.
42. Xiao JB, SL; Cannon, TD; Suzuki, Y; Viscidi, RP; Torrey, EF; Yolken, RH. Serological pattern consistent with infection with type I *Toxoplasma gondii* in mothers and risk of psychosis among adult offspring. *Microbes Infect.* 2009;11(13):1011-8.
43. Xiao JJ-B, L; Talbot, CC Jr; Yolken, RH. Differential effects of three canonical *Toxoplasma* strains on gene expression in human neuroepithelial cells. *Infect Immun.* 2011;79(3):1363-73.
44. Berdoy MW, JP; MacDonald, DW. Fatal Attraction in Rats Infected with *Toxoplasma gondii*. *Proc Biol Sci.* 2000;267(1452):1591-4.
45. Vyas AS-K, K; Giacomini, N; Boothroyd, JC; Sapolsku, RM. Behavioural changes induced by *Toxoplasma* infection in rodents are highly specific to aversion of cat odours. *Proc Nat Acad Sci USA.* 2007a;104:6442-7.
46. Kortbeek LdM, HE; Veldhuijzen, IK; Conynvan Spaendonck, MA. Population-based *Toxoplasma* seroprevalence study in The Netherlands. *Epidemiol Infect.* 2004;132(839-845).
47. Wittchen HU, Robins LN, Cottler LB, Sartorius N, Burke JD, Regier D. Cross-cultural feasibility, reliability and sources of variance of the Composite International Diagnostic Interview (CIDI). The Multicentre WHO/ADAMHA Field Trials. *The British journal of psychiatry : the journal of mental science.* 1991;159:645-53, 58.
48. Wacker H, Battegay R, Mullejans R, Schlosser C. Using the CIDI-C in the general population. *Psychiatry: A world perspective.* 1990;1:138-43.
49. Wittchen HU. Reliability and validity studies of the WHO-Composite International Diagnostic Interview (CIDI): A critical review. *Journal of psychiatric research.* 1994;28(1):57-84.

50. Wittchen HU, Burke JD, Semler G, Pfister H, Von Cranach M, Zaudig M. Recall and dating of psychiatric symptoms: test-retest reliability of time-related symptom questions in a standardized psychiatric interview. *Archives of general psychiatry*. 1989;46(5):437-43.
51. Flegr J, Hodny Z. Cat scratches, not bites, are associated with unipolar depression--cross-sectional study. *Parasit Vectors*. 2016;9:8.
52. Flegr JP, M; Balátová, P. Depressiveness and Neuroticism in Bartonella Seropositive and Seronegative Subjects - Preregistered Case-Controls Study. *Frontiers in Psychiatry*. 2018;9(314):1-14.
53. Yuksel Pea. The role of latent toxoplasmosis in the aetiopathogenesis of schizophrenia: the risk factor or an indication of a contact with cat? *Folia Parasitologica*. 2010;57(2):121-8.



**Supplementary Fig. 1.** Ratio of *T. gondii* IgG antibodies (on a log scale) in serum and citrated plasma in a subpopulation of 100 participants

† Adjusted for sex, age, level of education, North European ancestry, BMI, and clinical site location.

**Supplementary Table 1.** *T. gondii* IgG antibody levels according to diagnosis groups

Diagnosis groups	Model 1 <sup>†</sup>		Model 2 <sup>‡</sup>	
	$\beta$	P value	$\beta$	P value
Healthy controls	1.00 (ref)		-0.06	0.15
Remitted depression and/or anxiety	0.03	0.50	-0.06	0.25
Any current depression and/or anxiety disorder	0.09	0.11		
Current Dysthymia	0.03	0.76	0.02	0.38
Current Major Depressive Disorder	-0.008	0.91	-0.09	0.008
Current Social Phobia	0.05	0.54	-0.06	0.03
Current Panic Disorder	0.12	0.13	-0.01	0.58
Current Agoraphobia	0.08	0.30	0.03	0.36
Current Generalized Anxiety Disorder	0.05	0.52	-0.004	0.87

<sup>†</sup>Adjusted for sex, age, level of education, North European ancestry, BMI, and clinical site location.

<sup>‡</sup>Adjusted for the beforementioned sociodemographic variables, healthy controls, remitted depression and/or anxiety, and current dysthymia, MDD, SP, PD, AP, and GAD.

**Supplementary Table 2.** *T. gondii* IgG antibody levels according to severity measures

Severity measure	Crude		Adjusted Model <sup>†</sup>	
	$\beta$	P value	$\beta$	Adjusted P value
Depression:				
IDS-SR	0.002	0.93	-0.03	0.21
Anxiety:				
BAI	0.02	0.40	0.004	0.88
FQ	-0.008	0.74	-0.02	0.47
PSWQ	-0.03	0.24	-0.02	0.49
Cognitive reactivity (LEIDS-R):				
Aggression	-0.04	0.08	-0.01	0.75
Hopelessness / suicidality	-0.01	0.63	-0.01	0.65

<sup>†</sup>Adjusted for sex, age, level of education, North European ancestry, BMI, and clinical site location.